Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

0 Просмотры· 07/03/23
OncLive® On Air
OncLive® On Air
0 Подписчики
0
В

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Показать больше

 0 Комментарии sort   Сортировать по


Следующий